Mahmoudian, Armaghan http://orcid.org/0000-0002-1217-6375
Lohmander, L. Stefan http://orcid.org/0000-0002-5424-9448
Mobasheri, Ali http://orcid.org/0000-0001-6261-1286
Englund, Martin http://orcid.org/0000-0003-3320-2437
Luyten, Frank P. http://orcid.org/0000-0003-3186-0276
Article History
Accepted: 22 July 2021
First Online: 31 August 2021
Competing interests
: L.S.L declares that he serves as member of an AstraZeneca Data and Safety Monitoring Board, has acted as a consultant for the planning of phase II and III clinical trials for Paradigm Biopharmaceuticals Australia & Ireland, is a member of an expert group for assessing research proposals on musculoskeletal pain for Pfizer/Lilly USA, acts as a consultant for the scientific evaluation and publication of outcomes of an eHealth app for hip and knee osteoarthritis (Arthro Therapeutics Sweden), and was a member of an expert group for National Guidelines Osteoarthritis Care 2020 for the National Board of Health and Welfare Sweden. A.Mo. declares that he has acted as a consultant for Abbvie, AlphaSights, Artialis SA, Atheneum Partners, Flexion Therapeutics, Galapagos, GSK Consumer Healthcare, Guidepoint Global, Image Analysis Group, Kolon TissueGene, Novartis, Pacira Biosciences Inc, Pfizer Consumer Healthcare, Servier, Sterifarma, and Science Branding Communications; has received research funding from the European Commission (FP7, IMI, Marie Skłodowska-Curie, ES Struktūrinės Paramos), Versus Arthritis (Arthritis Research UK) and initiated research contracts with Merck KGaA and Kolon TissueGene; he has received speaker payments from Achē Laboratórios Farmacêuticos, the American College of Rheumatology, Bioiberica SA, the Korean Society for Osteoarthritis and Cartilage Repair, Laboratoires Expanscience, the Spanish Society of Rheumatology, Sanofi, the Heilongjiang Rheumatology Association and the Zhujiang Hospital of Southern Medical University; he currently serves as President of the Osteoarthritis Research Society International (OARSI), a member of the Advisory Board of Research Square and he is a member of the Scientific Advisory Board of Kolon TissueGene; however, none of the organizations listed above was involved in the conceptualization, design, data collection, analysis, decision to publish, or preparation of this manuscript. M.E. declares that he has received an honorarium for serving on a 1-day advisery board for Pfizer; he also serves as an Executive Board Member (Treasurer) for OARSI. A.Ma. and F.P.L. declare no competing interests.